Amicus Therapeutics (FOLD) reported second-quarter 2024 adjusted earnings of 6 cents per share, beating the Zacks Consensus Estimate of 3 cents. The company had incurred a loss of 7 cents per share in the year-ago quarter. Please note that the company achieved non-GAAP profitability for the first time in the reported quarter. The year-over-year improvement can be attributed to higher revenues from Galafold (migalastat) sales and incremental revenues from the sale of the newly approved combo drug, Pombiliti ...

| --- | --- | --- | --- | |--------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES | | | | | 2Q24 Results Conference Call & Webcast | | | | | August 8, 2024 | | | | | | | | | 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product can ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President and CEO Sebastien Martel - Chief Business Officer Dr. Jeff Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Dr. Mitchell Goldman - Chief Medical Officer Ellen Rosenberg - Chief Legal Officer Conference Call Participants Tazeen Ahmad - BofA Securities Ellie Merle - UBS Anupam Rama - ...

Amicus Therapeutics (FOLD) reported $126.67 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 34%. EPS of $0.06 for the same period compares to -$0.15 a year ago. The reported revenue represents a surprise of +4.90% over the Zacks Consensus Estimate of $120.76 million. With the consensus EPS estimate being $0.03, the EPS surprise was +100.00%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share FOLD NASDAQ Global Market (Mark One) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA ...

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.06 per share when it actually produced a loss of $0.02, delivering a surprise of 66.67%. Over the last four quarters, t ...

Exhibit 99.1 Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates Q2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year GalafoldQ2 Revenue of $110.8M, up 17% Year-over-Year Pombiliti + OpfoldaQ2 Revenue of $15.9M, up 44% from Q1 2024 Raising 2024 Total Revenue Growth Guidance to 26%-31% at CER and 2024 Galafold Growth Guidance to 14%-18% at CER Narrowing non-GAAP Operating Expense Guidance to $345M to $360M Non-GAAP Profitability Achieved in Q2 and H1 2024 with ...

The Board of Governors of the Federal Reserve System (the Fed) adopted Regulation II in 2011, establishing fees for debit-card transactions. Corner Post began operating in 2018 and filed its lawsuit challenging Regulation II in 2021, claiming it had incurred excessive interchange fees under the rule. The U.S. Court of Appeals for the Eighth Circuit ruled that Corner Post's opportunity to file suit had expired in 2017, six years after the rule first issued. "Because an APA plaintiff may not file suit and obt ...

Washington, D.C., June 11, 2024 (GLOBE NEWSWIRE) -- The U.S. Court of Appeals for the Tenth Circuit has reversed a district court decision in Johnson v. Smith that upheld a Kansas state law authorizing intrusive warrantless searches for dog training and handling businesses. The New Civil Liberties Alliance filed an amicus curiae brief explaining that the warrantless-search law infringes the Appellants' Fourth Amendment rights "to be secure in their persons, houses, papers, and effects, against unreasonable ...

Washington, D.C., June 05, 2024 (GLOBE NEWSWIRE) -- Today, the U.S. Court of Appeals for the Fifth Circuit issued a decision in National Association of Private Fund Managers v. Securities and Exchange Commission vacating SEC's recent final rule restricting—and in some cases prohibiting—certain common contractual agreements between private investment funds and investment advisers. Following the New Civil Liberties Alliance amicus curiae brief's advice, the Court declared that SEC exceeded its statutory autho ...